Lymph-targeted high-density lipoprotein-mimetic nanovaccine for multi-antigenic personalized cancer immunotherapy

Mingqi Liu,Yang Feng,Yougong Lu,Renqi Huang,Ying Zhang,Yanan Zhao,Ran Mo

DOI: https://doi.org/10.1126/sciadv.adk2444

IF: 13.6

2024-03-15

Science Advances

Abstract:Cancer vaccines show huge potential for cancer prevention and treatment. However, their efficacy remains limited due to weak immunogenicity regarding inefficient stimulation of cytotoxic T lymphocyte (CTL) responses. Inspired by the unique characteristic and biological function of high-density lipoprotein (HDL), we here develop an HDL-mimicking nanovaccine with the commendable lymph-targeted capacity to potently elicit antitumor immunity using lipid nanoparticle that is co-loaded with specific cancer cytomembrane harboring a collection of tumor-associated antigens and an immune adjuvant. The nanoparticulate impact is explored on the efficiency of lymphatic targeting and dendritic cell uptake. The optimized nanovaccine promotes the co-delivery of antigens and adjuvants to lymph nodes and maintains antigen presentation of dendritic cells, resulting in long-term immune surveillance as the elevated frequency of CTLs within lymphoid organs and tumor tissue. Immunization of nanovaccine suppresses tumor formation and growth and augments the therapeutic efficacy of checkpoint inhibitors notably on the high-stemness melanoma in the mouse models.

multidisciplinary sciences

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to improve the immunogenicity of cancer vaccines. In particular, it aims to effectively stimulate cytotoxic T - lymphocyte (CTL) responses by designing a lymph - targeted high - density lipoprotein (HDL) - mimicking nanovaccine, thereby enhancing anti - tumor immunity. Specifically, the researchers developed an HDL - mimicking nanovaccine. This vaccine can efficiently co - deliver multiple tumor - associated antigens carried by specific cancer cell membranes and immune adjuvants to lymph nodes, and maintain the antigen - presenting function of dendritic cells, ultimately leading to long - term immune surveillance and an increase in CTL frequency in lymphoid organs and tumor tissues. Moreover, this nanovaccine has a significant therapeutic effect on highly stem - like melanoma in mouse models. It can inhibit tumor formation and growth and enhance the efficacy of immune checkpoint inhibitors.

In short, this study aims to solve the problem of insufficient immunogenicity of existing cancer vaccines by designing a new type of nanovaccine, especially when targeting tumors derived from tumor stem cells with low immunogenicity, to improve the preventive and therapeutic effects of vaccines.